Body

Study reports REVLIMID activity in patients with relapsed/refractory mantle-cell lymphoma

Source:

ASH presentation shows continued treatment with VIDAZA improves responses in higher-risk MDS

Source:

First 3D images obtained of core component of molecular machinery used for cell reproduction

For the first time, structural biologists have managed to obtain the detailed three-dimensional structure of one of the proteins that form the core of the complex molecular machine, called the replisome, that plant and animal cells assemble to copy their DNA as the first step in cell reproduction.

Reforms needed in health care services for adolescents

WASHINGTON -- Current health services for adolescents are fragmented and poorly designed to meet the health needs of all of the nation's adolescents, says a new report from the National Research Council and Institute of Medicine. Although most U.S. adolescents are healthy, many engage in risky behavior, develop unhealthy habits, and have physical and mental conditions that can jeopardize their immediate and future health. Health care providers need better training in how to meet the specific health needs of those aged 10 to 19, said the committee that wrote the report.

When 2 + 2 = major anxiety: Math performance in stressful situations

Imagine you are sitting in the back of a classroom, daydreaming about the weekend. Then, out of nowhere, the teacher calls upon you to come to the front the room and solve a math problem. In front of everyone. If just reading this scenario has given you sweaty palms and an increased heart rate, you are not alone. Many of us have experienced math anxiety and in a new report in Current Directions in Psychological Science, a journal of the Association for Psychological Science, University of Chicago psychologist Sian L.

Doctors raise questions, concerns about FDA suicide warning

SEATTLE, December 8, 2008—Medical specialists at the nation's largest professional meeting on epilepsy discussed multiple questions and concerns they have about data presented by the FDA in support of its recent suicide alert on anticonvulsant drugs (AEDs) and the potential effect of the federal agency's analyses on clinical practice and the way AED drug trials are to be conducted in the future.

New therapy prevents dangerous side effect for lymphoma patients

SAN FRANCISCO - Patients respond well to a new three-drug combination for indolent B cell lymphoma that also spares them prolonged, potentially lethal, suppression of blood production in the bone marrow, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years

SAN FRANCISCO - More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

Pine bark reduces inflammatory marker CRP in osteoarthritis

Osteoarthritis (OA), a type of arthritis caused by the breakdown and loss of cartilage, affects more than 20 million Americans. While the most common prescription to treat OA is non-steroidal anti-inflammatory drugs (NSAIDs), many seek alternative treatments because of the side effects associated with these drugs. Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, has been shown to reduce osteoarthritis in multiple studies.

Hepatitis C treatment reduces the virus but liver damage continues

Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.

Drug combination improves or stabilizes disease for relapsed multiple myeloma patients

ROCHESTER, Minn. -- Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment.

Leading US cancer organizations unite against the growing global cancer burden

Source:

Promising new drug blocks mutation in bone marrow cancers

PORTLAND, Ore. – Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers.

The oral drug, called CYT387, was tested in mice as well as in human cells. In both cases, it blocked the growth of certain bone marrow cancers called myeloproliferative disorders, also referred to as MPDs.

The research will be presented Tuesday, Dec. 9, at 7 a.m. during the 50th annual American Society of Hematology conference in San Francisco.

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Source:

Rust-proof -- even without chromium